Cancers
Combined Use of Savi Scout and Magtrace for Non-Palpable Breast Cancer: A Retrospective Study
By Claire Lloyd-Davies and Abdul Kasem.
Abstract
Background
Non-palpable breast cancer management has become less invasive and more efficient, driven by advances in tumor localization and sentinel lymph node (SLN) identification. Savi Scout, using a radar-based localization system, can be implanted into the tumor before neoadjuvant systemic therapy (NST). Magtrace, a superparamagnetic iron oxide nanoparticle for SLN detection, can be administered preoperatively. This study evaluated combining Savi Scout and Magtrace for breast-conserving surgery and SLN biopsy in non-palpable breast cancer.
Methods
Patients who underwent breast-conserving surgery and SLN biopsy for non-palpable breast cancer using Savi Scout and Magtrace between December 2022 and June 2026 at HCA Healthcare London Bridge Hospital were retrospectively identified. Outcomes included successful tumor localization, SLN identification, intraoperative signal detection failure, margin status, re-excision rate and staining.